Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205

NANOBIOTIX (NANO)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

NANOBIOTIX : and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 08:40am CEST
Nanobiotix and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

01.28.2013

An event organized by the European Technology Platform of Nanomedicine in the framework of the World Cancer Day

Paris and Lyon, France, January 28th, 2013 - Nanobiotix and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA) today announce their participation to the European event on February the 1st organized by ETPN (European Technology Platform of Nanomedicine). Similar events will be organized in parallel across Europe: France, United Kingdom, Germany and Portugal. Nano World Cancer Day is an event organized by the ETPN highlighting the importance of nanomedicine research for cancer on the European level.

"How nanomedicine contributes to better cancer diagnostic and therapy"

Radiotherapy, chemotherapy and surgery are part of the therapeutic arsenal for patients with cancer. New technologies associated with nanoparticles could provide more effective solutions to personalize diagnoses and treat these diseases, while improving targeted drug delivery and reducing side effects and collateral damages on the body. These breakthrough therapies based on nanomedicine contribute to solving this paradigm and are already a reality, with concrete results, 60 nano-products on the market and more than 70 in the pipeline. Nanomedicine can go further in bringing new therapeutic mode of action into cells. For instance, nanoparticles can already be injected into the tumor and then be activated to produce physical effect and destroy cancer cells locally.

Across the parallel European press events, leading international actors in the field will introduce examples highlighting the key role of nanomedicine for cancer therapy, diagnoses and imaging. This year, these actors across Europe are:

National Cancer organizations: CLARA (FR), Comprehensive Cancer Center (Charité University Hospital) (DE), International Iberian Nanotechnology Laboratory (PT) and Instituto Português de Oncologia do Porto (PT).

SMEs: Nanobiotix (FR & DE).

Universities / Public laboratories: Thomas Jefferson University, Philadelphia, US (FR), Université Paris Sud, Institut Galien Paris-Sud / CNRS (FR), Ludwig-Maximilians University München (DE), Aachen University Hospital (DE), Universidad de Santiago de Compostela (Spain), University of Lisboa/ Faculty of Pharmacy (PT), Leeds University (UK).

 Leading local experts involved in the Paris event:

-          Dr. Amaury MARTIN, Secretary General of CLARA (Lyon Rhône-Alpes Auvergne Cancer Research Cluster), Lyon

-          Dr. Laurent LEVY, Vice Chairman ETPN, CEO of Nanobiotix, Paris

-          Pr. Bo LU, MD, Thomas Jefferson University Hospital, Professor in the Department of Radiation Oncology and Director of the department's Division of Molecular Radiation Biology, Philadelphia

-          Pr. Elias FATTAL, Paris Sud University, Institut Galien Paris-Sud, CNRS-UMR 8612, Faculty of Pharmacy, Châtenay-Malabry.

This conference will give an overview on nanomedicine for cancer: what are the key areas of research? What are the new methods of diagnosis? What are the new treatments in development? What are the first results? What are the products used every day?

Videos of the Paris event will be available on February the 4th 2013 for the World Cancer Day.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NANOBIOTIX
04/08 NANOBIOTIX : completes 25m private placement
04/06 NANOBIOTIX : Financial | NANOBIOTIX launches capital increase by means of an acc..
04/04 NANOBIOTIX : Corporate | Nanobiotix expands its clinical development in Head and..
04/04 NANOBIOTIX : Nanobiotix expands its clinical development in Head and Neck cancer..
03/23 SCIENTIFIC CLINICAL | NANOBIOTIX : the Independent Data Monitoring Committee rec..
03/23 NANOBIOTIX : the Independent Data Monitoring Committee recommends the continuati..
03/07 NANOBIOTIX : Scientific Clinical | Nanobiotix to present preclinical data on nan..
03/07 NANOBIOTIX : Nanobiotix to present preclinical data on nanoparticle radioenhance..
02/28 NANOBIOTIX : Financial | Nanobiotix 2016 Q4 and annual revenues
02/07 NANOBIOTIX : appoints Oncology industry veteran as Chief Operating Officer
More news
Sector news : Biotechnology & Medical Research - NEC
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 NANOMETRICS : Well-Positioned In A Promising Industry
2015 Nanometrics' (NANO) CEO Timothy Stultz on Q4 2014 Results - Earnings Call Tra..
2015 Nanometrics Incorporated (NANO) Q4 2014 Results - Earnings Call Webcast
2015 Nanometrics beats by $0.03, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Financials (€)
Sales 2016 3,38 M
EBIT 2016 -19,7 M
Net income 2016 -19,7 M
Finance 2016 7,51 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 84,3x
EV / Sales 2017 21,8x
Capitalization 293 M
More Financials
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | 4-Traders
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 33,5 €
Spread / Average Target 101%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Laurent Lévy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Alain Dostie Chief Operating Officer
Philippe Mauberna Chief Financial Officer
Elsa Borghi Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX7.97%314
INCYTE CORPORATION22.68%25 166
QUINTILES IMS HOLDINGS..8.15%19 405
LONZA GROUP AG8.28%11 101
CELLTRION, INC.--.--%9 762
SEATTLE GENETICS, INC.23.82%9 319
More Results